PRQR
ProQR Therapeutics NV
NASDAQ · Healthcare · Biotechnology · NL
$1.31
+0.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.35
From 52W high−57.05%
Volume747836.00
Market cap$184.87M
P/E (TTM)—
P/S (TTM)8.9x
Div yield—
Key dataOct 19, 2026
Open
$1.35
From 52W high
−57.05%
Volume
747836.00
Market cap
$184.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
P/E (TTM)
—
RSI (14)
23.7
MomentumView details →
1D Return
+0.00%
YTD Return
−34.16%
SummaryUpdated Jun 1, 2026
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a Dutch biopharmaceutical company founded in 2012 and headquartered in Leiden, the Netherlands. The company went public in September 2014 and specializes in developing RNA-based therapeutic treatments for rare genetic disorders. ProQR focuses primarily on inherited diseases that cause blindness and other serious genetic conditions, utilizing innovative RNA editing and antisense oligonucleotide technologies to address previously untreatable genetic mutations.
Similar companies
Latest newsMore news →
ProQR Therapeutics dosed the first participant in the Phase 1 clinical trial of AX-0811 in healthy volunteers, marking the start of the study.41d agoProQR Therapeutics priced an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share for gross proceeds of $50.0 million.117d ago